UK markets closed

Syros Pharmaceuticals, Inc. (0LC7.L)

LSE - LSE Delayed price. Currency in USD
Add to watchlist
6.78+1.45 (+27.20%)
At close: 05:08PM BST
Full screen
Previous close5.33
Open6.78
Bid0.00 x N/A
Ask0.00 x N/A
Day's range6.78 - 6.78
52-week range6.78 - 6.78
Volume0
Avg. volumeN/A
Market capN/A
Beta (5Y monthly)1.61
PE ratio (TTM)N/A
EPS (TTM)-1.55
Earnings date03 Nov 2022 - 07 Nov 2022
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Business Wire

    Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    CAMBRIDGE, Mass., October 05, 2022--Syros Pharmaceuticals (Nasdaq: SYRS), a leader in the development of medicines that control the expression of genes, today announced the grant of a restricted stock unit (RSU) award for 1,260 shares of Syros common stock to one newly hired employee in connection with the employee’s commencement of employment with Syros. These RSUs were granted as a material inducement to employment in accordance with Nasdaq Listing Rule 5635(c)(4).

  • Business Wire

    Syros Announces Closing of Merger with Tyme Technologies and Concurrent Private Placement

    CAMBRIDGE, Mass., September 16, 2022--Syros Pharmaceuticals, Inc. (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced the closing of its merger with Tyme Technologies, Inc., pursuant to which Syros acquired TYME, including its pipeline assets and net cash at closing of approximately $60 million. Shares of the combined company will trade on Nasdaq under the ticker symbol "SYRS."

  • Business Wire

    Syros and Tyme Technologies Announce Stockholder Approval of Merger

    CAMBRIDGE, Mass. & BEDMINSTER, N.J., September 15, 2022--Syros Pharmaceuticals, Inc. (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, and Tyme Technologies, Inc. (NASDAQ:TYME) today announced the results of the special meetings of the stockholders of Syros and TYME, respectively, each held on September 15, 2022. At TYME’s special meeting, TYME’s stockholders voted in favor of all proposals, including the proposal to adopt the agreement and plan of mer